| 51 |
28431666 | GLP-1 receptor agonists and heart failure in diabetes. | 2017 Apr |
1 |
| 52 |
28539578 | Drug-Induced Inhibition of Angiotensin Converting Enzyme and Dipeptidyl Peptidase 4 Results in Nearly Therapy Resistant Bradykinin Induced Angioedema: A Case Report. | 2017 May 25 |
1 |
| 53 |
28622738 | Assessment of the Risk of Hospitalization for Heart Failure With Dipeptidyl Peptidase-4 Inhibitors, Saxagliptin, Alogliptin, and Sitagliptin in Patients With Type 2 Diabetes, Using an Alternative Measure to the Hazard Ratio. | 2017 Jul |
1 |
| 54 |
28859968 | Dipeptidyl peptidase-4 independent cardiac dysfunction links saxagliptin to heart failure. | 2017 Dec 1 |
2 |
| 55 |
28878934 | Postauthorization safety study of the DPP-4 inhibitor saxagliptin: a large-scale multinational family of cohort studies of five outcomes. | 2017 |
1 |
| 56 |
28932239 | Computational Analysis of Gynura bicolor Bioactive Compounds as Dipeptidyl Peptidase-IV Inhibitor. | 2017 |
1 |
| 57 |
28948519 | The Use of Saxagliptin in People with Type 2 Diabetes in France: The Diapazon Epidemiological Study. | 2017 Oct |
1 |
| 58 |
28984487 | Dapagliflozin and saxagliptin tablets for adults with type 2 diabetes. | 2017 Dec |
1 |
| 59 |
26724938 | Healthcare Costs Among Adults with Type 2 Diabetes Initiating DPP-4 Inhibitors. | 2016 Jan |
1 |
| 60 |
26824365 | Novel Therapeutic Approaches in Diabetes. | 2016 |
1 |
| 61 |
26872429 | Reduced DPP4 activity improves insulin signaling in primary human adipocytes. | 2016 Mar 11 |
2 |
| 62 |
26878666 | Pharmacokinetic, pharmacodynamic and clinical evaluation of saxagliptin in type 2 diabetes. | 2016 |
1 |
| 63 |
26923222 | Saxagliptin for the treatment of diabetes - a focus on safety. | 2016 May |
1 |
| 64 |
27030121 | [Cardiovascular outcome clinical trials in type 2 diabetes mellitus: what are the epidemiological and methodological evidence and the first evaluations to date?]. | 2016 Mar |
1 |
| 65 |
27075625 | NRF2 activation by antioxidant antidiabetic agents accelerates tumor metastasis. | 2016 Apr 13 |
1 |
| 66 |
27093207 | [Treatment of patients with type 2 diabetes mellitus: cardiovascular safety of incretin-based therapy supported by the ELIXA and TECOS trials]. | 2016 Apr |
2 |
| 67 |
27106831 | Outcome studies and safety as guide for decision making in treating patients with type 2 diabetes. | 2016 Mar |
1 |
| 68 |
27321342 | Efficacy and safety of saxagliptin, a dipeptidyl peptidase-4 inhibitor, in hemodialysis patients with diabetic nephropathy: A randomized open-label prospective trial. | 2016 Jun |
2 |
| 69 |
27347354 | Cardiovascular safety of dipeptidyl peptidase-4 inhibitors: recent evidence on heart failure. | 2016 |
1 |
| 70 |
27388897 | Comparison of charges and resource use associated with saxagliptin and sitagliptin. | 2016 Dec |
2 |
| 71 |
27402391 | Saxagliptin Efficacy and Safety in Patients With Type 2 Diabetes and Moderate Renal Impairment. | 2016 Sep |
1 |
| 72 |
27403645 | One-year efficacy and safety of saxagliptin add-on in patients receiving dapagliflozin and metformin. | 2016 Nov |
1 |
| 73 |
25331711 | Pharmacokinetics and clinical use of incretin-based therapies in patients with chronic kidney disease and type 2 diabetes. | 2015 Jan |
1 |
| 74 |
25565858 | Overview of saxagliptin efficacy and safety in patients with type 2 diabetes and cardiovascular disease or risk factors for cardiovascular disease. | 2015 |
1 |
| 75 |
25656169 | Impact of treatment with saxagliptin on glycaemic stability and β-cell function in the SAVOR-TIMI 53 study. | 2015 May |
1 |
| 76 |
25852133 | Cardiovascular effects of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes. | 2015 May |
1 |
| 77 |
25889498 | Determinants of saxagliptin use among patients with type 2 diabetes mellitus treated with oral anti-diabetic drugs. | 2015 Apr 2 |
1 |
| 78 |
26009231 | Heart failure in diabetes: effects of anti-hyperglycaemic drug therapy. | 2015 May 23 |
1 |
| 79 |
26089691 | Clinical trial simulation methods for estimating the impact of DPP-4 inhibitors on cardiovascular disease. | 2015 |
2 |
| 80 |
26164634 | Oral hypoglycemic agents and the heart failure conundrum: Lessons from and for outcome trials. | 2015 Aug |
1 |
| 81 |
26290759 | Dipeptidyl Peptidase-4 Inhibition May Stimulate Progression of Carcinoid Tumor. | 2015 |
2 |
| 82 |
26389773 | Combination therapy with saxagliptin and dapagliflozin for the treatment of type 2 diabetes. | 2015 |
2 |
| 83 |
26403305 | Saxagliptin: A Review in Type 2 Diabetes. | 2015 Oct |
1 |
| 84 |
26578430 | Utility of Saxagliptin in the Treatment of Type 2 Diabetes: Review of Efficacy and Safety. | 2015 Nov |
1 |
| 85 |
24320733 | The dipeptidylpeptidase-IV inhibitors sitagliptin, vildagliptin and saxagliptin do not impair innate and adaptive immune responses. | 2014 Jun |
1 |
| 86 |
24457090 | Synthesis and biological evaluation of all eight stereoisomers of DPP-IV inhibitor saxagliptin. | 2014 Feb 15 |
3 |
| 87 |
24493030 | Effects of incretin-based therapy in patients with heart failure and myocardial infarction. | 2014 Sep |
1 |
| 88 |
24515526 | Clinical effects of exposure to DPP-4 inhibitors as reported to the National Poison Data System. | 2014 Jun |
1 |
| 89 |
24580063 | A retrospective review of isolated gliptin-exposure cases reported to a state poison control system. | 2014 Mar |
2 |
| 90 |
24886621 | The dipeptidyl peptidase-4 inhibitor saxagliptin improves function of circulating pro-angiogenic cells from type 2 diabetic patients. | 2014 May 14 |
3 |
| 91 |
24914244 | Incidence of pancreatitis and pancreatic cancer in a randomized controlled multicenter trial (SAVOR-TIMI 53) of the dipeptidyl peptidase-4 inhibitor saxagliptin. | 2014 Sep |
1 |
| 92 |
24993124 | Alogliptin; a review of a new dipeptidyl peptidase-4 (DPP-4) inhibitor for the treatment of type 2 diabetes mellitus. | 2014 |
1 |
| 93 |
25050065 | Profile of saxagliptin in the treatment of type 2 diabetes: focus on Japanese patients. | 2014 |
4 |
| 94 |
25171159 | DPP-4 inhibitors: pharmacological differences and their clinical implications. | 2014 Sep |
1 |
| 95 |
25283263 | Dipeptidyl-peptidase-4 Inhibitors and Heart Failure: Class Effect, Substance-Specific Effect, or Chance Effect? | 2014 Dec |
1 |
| 96 |
25504156 | Retrospective analysis of long-term adherence to and persistence with DPP-4 inhibitors in US adults with type 2 diabetes mellitus. | 2014 Dec |
1 |
| 97 |
25646943 | Efficacy and safety of saxagliptin as add-on therapy in type 2 diabetes. | 2014 Oct |
1 |
| 98 |
23137182 | Saxagliptin overview: special focus on safety and adverse effects. | 2013 Jan |
2 |
| 99 |
23564755 | Baseline characteristics of the patient population in the Saxagliptin Assessment of Vascular Outcomes Recorded in patients with diabetes mellitus (SAVOR)-TIMI 53 trial. | 2013 Jul |
1 |
| 100 |
23707531 | Cardiovascular pleiotropic actions of DPP-4 inhibitors: a step at the cutting edge in understanding their additional therapeutic potentials. | 2013 Sep |
1 |